Literature DB >> 27055916

Apparent diffusion coefficient values are superior to transrectal ultrasound-guided prostate biopsy for the assessment of prostate cancer aggressiveness.

Chunmei Li1, Min Chen1, Jianye Wang2, Xuan Wang2, Wei Zhang3, Chen Zhang1.   

Abstract

Background Few studies have focused on comparing the utility of diffusion-weighted imaging (DWI) and transrectal ultrasound (TRUS)-guided biopsy in predicting prostate cancer aggressiveness. Whether apparent diffusion coefficient (ADC) values can provide more information than TRUS-guided biopsy should be confirmed. Purpose To retrospectively assess the utility of ADC values in predicting prostate cancer aggressiveness, compared to the TRUS-guided prostate biopsy Gleason score (GS). Material and Methods The DW images of 54 patients with biopsy-proven prostate cancer were obtained using 1.5-T magnetic resonance (MR). The mean ADC values of cancerous areas and biopsy GS were correlated with prostatectomy GS and D'Amico clinical risk scores, respectively. Meanwhile, the utility of ADC values in identifying high-grade prostate cancer (with Gleason 4 and/or 5 components in prostatectomy) in patients with a biopsy GS ≤ 3 + 3 = 6 was also evaluated. Results A significant negative correlation was found between mean ADC values of cancerous areas and the prostatectomy GS ( P < 0.001) and D'Amico clinical risk scores ( P < 0.001). No significant correlation was found between biopsy GS and prostatectomy GS ( P = 0.140) and D'Amico clinical risk scores ( P = 0.342). Patients harboring Gleason 4 and/or 5 components in prostatectomy had significantly lower ADC values than those harboring no Gleason 4 and/or 5 components ( P = 0.004). Conclusion The ADC values of cancerous areas in the prostate are a better indicator than the biopsy GS in predicting prostate cancer aggressiveness. Moreover, the use of ADC values can help identify the presence of high-grade tumor in patients with a Gleason score ≤ 3 + 3 = 6 during biopsy.

Entities:  

Keywords:  Transrectal ultrasound-guided (TRUS) biopsy; aggressiveness; apparent diffusion coefficient; diffusion weighted-imaging (DWI); prostate cancer

Mesh:

Year:  2016        PMID: 27055916     DOI: 10.1177/0284185116639764

Source DB:  PubMed          Journal:  Acta Radiol        ISSN: 0284-1851            Impact factor:   1.990


  5 in total

1.  Reduced field-of-view and multi-shot DWI acquisition techniques: Prospective evaluation of image quality and distortion reduction in prostate cancer imaging.

Authors:  Edward M Lawrence; Yuxin Zhang; Jitka Starekova; Zihan Wang; Ali Pirasteh; Shane A Wells; Diego Hernando
Journal:  Magn Reson Imaging       Date:  2022-08-06       Impact factor: 3.130

2.  Role of multi-parametric MRI of the prostate for screening and staging: Experience with over 1500 cases.

Authors:  Geoffrey Gaunay; Vinay Patel; Paras Shah; Daniel Moreira; Simon J Hall; Manish A Vira; Michael Schwartz; Jessica Kreshover; Eran Ben-Levi; Robert Villani; Ardeshir Rastinehad; Lee Richstone
Journal:  Asian J Urol       Date:  2016-11-22

3.  The Apparent Diffusion Coefficient (ADC) is a useful biomarker in predicting metastatic colon cancer using the ADC-value of the primary tumor.

Authors:  Elias Nerad; Andrea Delli Pizzi; Doenja M J Lambregts; Monique Maas; Sharan Wadhwani; Frans C H Bakers; Harrie C M van den Bosch; Regina G H Beets-Tan; Max J Lahaye
Journal:  PLoS One       Date:  2019-02-05       Impact factor: 3.240

4.  Fully automated detection and localization of clinically significant prostate cancer on MR images using a cascaded convolutional neural network.

Authors:  Lina Zhu; Ge Gao; Yi Zhu; Chao Han; Xiang Liu; Derun Li; Weipeng Liu; Xiangpeng Wang; Jingyuan Zhang; Xiaodong Zhang; Xiaoying Wang
Journal:  Front Oncol       Date:  2022-09-29       Impact factor: 5.738

5.  Discrimination between clinical significant and insignificant prostate cancer with apparent diffusion coefficient - a systematic review and meta analysis.

Authors:  Hans-Jonas Meyer; Andreas Wienke; Alexey Surov
Journal:  BMC Cancer       Date:  2020-05-27       Impact factor: 4.430

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.